| Dr Andrew Kent Sanderson Ii, MD | |
|
417 State St Ste 121, Bangor, ME 04401-6630 | |
| (207) 973-4266 | |
| Not Available |
| Full Name | Dr Andrew Kent Sanderson Ii |
|---|---|
| Gender | Male |
| Speciality | Gastroenterology |
| Experience | 23 Years |
| Location | 417 State St Ste 121, Bangor, Maine |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144431552 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Eastern Maine Medical Center | Bangor, ME | Hospital |
| Adventist Healthcare White Oak Medical Center | Silver spring, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Adventist Physician Services Inc | 4284631540 | 123 |
| Eastern Maine Medical Center | 2062315161 | 577 |
News Archive
Scientists at Karolinska Institutet and Karolinska University Hospital in Sweden have discovered a new explanation for severe early infant epilepsy. Mutations in the gene encoding the protein KCC2 can cause the disease, hereby confirming an earlier theory.
A research group led by Project Professor Morioka Ichiro and Assistant Professor Iwatani Sota in collaboration with Doctor Miyawaki Atsushi have clinically proven that a fluorescent protein sourced from Japanese eel muscles can be used to accurately detect unconjugated bilirubin in newborns.
Biomedical engineers have grown miniature human blood vessels that exhibit many of the symptoms and drug reactions associated with Hutchinson-Gilford Progeria Syndrome - an extremely rare genetic disease that causes symptoms resembling accelerated aging in children.
e-Therapeutics plc announced today interim results from its phase Ia UK study evaluating the safety, dosing and anti-tumour activity of ETS2101 (dexanabinol) in patients with advanced solid tumours.
› Verified 2 days ago
| Entity Name | Howard University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033163597 PECOS PAC ID: 0941109565 Enrollment ID: O20040102000561 |
News Archive
Scientists at Karolinska Institutet and Karolinska University Hospital in Sweden have discovered a new explanation for severe early infant epilepsy. Mutations in the gene encoding the protein KCC2 can cause the disease, hereby confirming an earlier theory.
A research group led by Project Professor Morioka Ichiro and Assistant Professor Iwatani Sota in collaboration with Doctor Miyawaki Atsushi have clinically proven that a fluorescent protein sourced from Japanese eel muscles can be used to accurately detect unconjugated bilirubin in newborns.
Biomedical engineers have grown miniature human blood vessels that exhibit many of the symptoms and drug reactions associated with Hutchinson-Gilford Progeria Syndrome - an extremely rare genetic disease that causes symptoms resembling accelerated aging in children.
e-Therapeutics plc announced today interim results from its phase Ia UK study evaluating the safety, dosing and anti-tumour activity of ETS2101 (dexanabinol) in patients with advanced solid tumours.
› Verified 2 days ago
| Entity Name | Kaiser Foundation Health Plan Of The Mid-atlantic States,inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952461816 PECOS PAC ID: 3779495858 Enrollment ID: O20040105000308 |
News Archive
Scientists at Karolinska Institutet and Karolinska University Hospital in Sweden have discovered a new explanation for severe early infant epilepsy. Mutations in the gene encoding the protein KCC2 can cause the disease, hereby confirming an earlier theory.
A research group led by Project Professor Morioka Ichiro and Assistant Professor Iwatani Sota in collaboration with Doctor Miyawaki Atsushi have clinically proven that a fluorescent protein sourced from Japanese eel muscles can be used to accurately detect unconjugated bilirubin in newborns.
Biomedical engineers have grown miniature human blood vessels that exhibit many of the symptoms and drug reactions associated with Hutchinson-Gilford Progeria Syndrome - an extremely rare genetic disease that causes symptoms resembling accelerated aging in children.
e-Therapeutics plc announced today interim results from its phase Ia UK study evaluating the safety, dosing and anti-tumour activity of ETS2101 (dexanabinol) in patients with advanced solid tumours.
› Verified 2 days ago
| Entity Name | Adventist Physician Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376623207 PECOS PAC ID: 4284631540 Enrollment ID: O20061030000122 |
News Archive
Scientists at Karolinska Institutet and Karolinska University Hospital in Sweden have discovered a new explanation for severe early infant epilepsy. Mutations in the gene encoding the protein KCC2 can cause the disease, hereby confirming an earlier theory.
A research group led by Project Professor Morioka Ichiro and Assistant Professor Iwatani Sota in collaboration with Doctor Miyawaki Atsushi have clinically proven that a fluorescent protein sourced from Japanese eel muscles can be used to accurately detect unconjugated bilirubin in newborns.
Biomedical engineers have grown miniature human blood vessels that exhibit many of the symptoms and drug reactions associated with Hutchinson-Gilford Progeria Syndrome - an extremely rare genetic disease that causes symptoms resembling accelerated aging in children.
e-Therapeutics plc announced today interim results from its phase Ia UK study evaluating the safety, dosing and anti-tumour activity of ETS2101 (dexanabinol) in patients with advanced solid tumours.
› Verified 2 days ago
| Entity Name | Unity Health Care Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093894172 PECOS PAC ID: 3476647264 Enrollment ID: O20071024000456 |
News Archive
Scientists at Karolinska Institutet and Karolinska University Hospital in Sweden have discovered a new explanation for severe early infant epilepsy. Mutations in the gene encoding the protein KCC2 can cause the disease, hereby confirming an earlier theory.
A research group led by Project Professor Morioka Ichiro and Assistant Professor Iwatani Sota in collaboration with Doctor Miyawaki Atsushi have clinically proven that a fluorescent protein sourced from Japanese eel muscles can be used to accurately detect unconjugated bilirubin in newborns.
Biomedical engineers have grown miniature human blood vessels that exhibit many of the symptoms and drug reactions associated with Hutchinson-Gilford Progeria Syndrome - an extremely rare genetic disease that causes symptoms resembling accelerated aging in children.
e-Therapeutics plc announced today interim results from its phase Ia UK study evaluating the safety, dosing and anti-tumour activity of ETS2101 (dexanabinol) in patients with advanced solid tumours.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Andrew Kent Sanderson Ii, MD 43 Whiting Hill Rd Ste 300, Brewer, ME 04412-1006 Ph: (207) 973-5000 | Dr Andrew Kent Sanderson Ii, MD 417 State St Ste 121, Bangor, ME 04401-6630 Ph: (207) 973-4266 |
News Archive
Scientists at Karolinska Institutet and Karolinska University Hospital in Sweden have discovered a new explanation for severe early infant epilepsy. Mutations in the gene encoding the protein KCC2 can cause the disease, hereby confirming an earlier theory.
A research group led by Project Professor Morioka Ichiro and Assistant Professor Iwatani Sota in collaboration with Doctor Miyawaki Atsushi have clinically proven that a fluorescent protein sourced from Japanese eel muscles can be used to accurately detect unconjugated bilirubin in newborns.
Biomedical engineers have grown miniature human blood vessels that exhibit many of the symptoms and drug reactions associated with Hutchinson-Gilford Progeria Syndrome - an extremely rare genetic disease that causes symptoms resembling accelerated aging in children.
e-Therapeutics plc announced today interim results from its phase Ia UK study evaluating the safety, dosing and anti-tumour activity of ETS2101 (dexanabinol) in patients with advanced solid tumours.
› Verified 2 days ago
Eddy Karnabi, MD PHD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1 Northeast Dr, Bangor, ME 04401 Phone: 207-275-3800 | |
Dr. Theodore William James, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 417 State St Ste 121, Bangor, ME 04401 Phone: 207-973-4266 | |
Fnu Kaleemullah, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 489 State St, Bangor, ME 04401 Phone: 207-973-7314 | |
Sverrir I Gunnarsson, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1 Northeast Dr, Bangor, ME 04401 Phone: 207-275-3800 | |
Liga Yusvirazi, MD Gastroenterology Medicare: Medicare Enrolled Practice Location: 360 Broadway, Bangor, ME 04401 Phone: 207-907-3283 | |
Ilsa Annetta Shulman, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 900 Broadway, Bangor, ME 04401 Phone: 207-907-3300 Fax: 207-907-1923 | |
Dr. Michael Paul Sighinolfi, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 360 Broadway Ste 100, Bangor, ME 04401 Phone: 207-907-3550 Fax: 207-907-3562 |